← PTC Therapeutics, Inc. (PTCT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
PTC Therapeutics, Inc. (PTCT)
Pharmaceutical Preparations · market cap $5.3B · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
11
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
PTC Therapeutics (PTCT) is a ~$647M market-cap rare-disease pharmaceutical company focused on orally administered small molecules and gene therapies targeting post-transcriptional control mechanisms. Its pipeline spans multiple orphan indications including Duchenne Muscular Dystrophy (ataluren, Phase 3), Friedreich Ataxia (vatiquinone, Phase 3), and Phenylketonuria (sepiapterin, Phase 3). The company reported a striking $1.73B in 2025 revenue alongside a $683M net gain, a sharp reversal from prior years of heavy losses, and holds $834M in cash with ~42 months of runway.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ataluren | Phase 3 | Duchenne Muscular Dystrophy |
| EPI-743 | Phase 2 | Leigh Syndrome |
| PTC923 | Phase 3 | BH4 Deficiency |
| EPI-589 | Phase 2 | Amyotrophic Lateral Sclerosis |
| EPI-743 400 mg | Phase 2 | Friedreich's Ataxia |
| EPI-743 15 mg/kg | Phase 2 | Leigh Syndrome |
| CNSA-001 | Phase 2 | Gastroparesis |
| Ataluren (PTC124®) | Phase 3 | Cystic Fibrosis |
| Vatiquinone | Phase 3 | Friedreich Ataxia |
| Sepiapterin | Phase 3 | Phenylketonuria |
| PTC124 | Phase 2 | Cystic Fibrosis |
Price & technical context
3-month
-23.0%
6-month
-6.7%
12-month
+3.4%
52-wk range
$62.28–$89.55
vs 50-day MA
-8.2%
vs 200-day MA
-11.2%
Realized vol
52.0%
Max drawdown
-36.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PTCT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.